Related Experiment Videos
Glucose-lowering effect of BTS 67 582
1Department of Pharmaceutical & Biological Sciences, Aston University, Birmingham.
British Journal of Pharmacology
|January 8, 1998
Summary
BTS 67 582, a novel compound, effectively lowers blood glucose in rats by stimulating insulin release. This hypoglycemic effect is dose-dependent and mediated through enhanced insulin secretion, crucial for glucose regulation.
Area of Science:
- Pharmacology
- Endocrinology
- Metabolic Research
Background:
- Understanding novel hypoglycemic agents is crucial for diabetes management.
- The compound BTS 67 582 (1,1-dimethyl-2(2-morpholinophenyl) guanidine fumarate) has shown potential in preclinical studies.
Purpose of the Study:
- To investigate the acute hypoglycemic effect of BTS 67 582 in normal rats.
- To elucidate the mechanism underlying the glucose-lowering action of BTS 67 582, particularly its effect on insulin secretion.
Main Methods:
- Oral administration of BTS 67 582 (100 mg/kg) to normal rats.
- Intravenous glucose tolerance tests (IVGTT) and hyperglycemic clamp studies.
- Assessment of plasma glucose and insulin concentrations.
- Studies involving somatostatin infusion and diabetic rat models (BB/S rats).
Main Results:
- BTS 67 582 significantly reduced basal plasma glucose levels within 1 hour, with maximum effects observed at 2-3 hours.
- A marked increase in plasma insulin concentrations (3-fold) was observed concurrently with glucose reduction.
- The compound enhanced glucose utilization during IVGTT and hyperglycemic clamp studies, indicating improved insulin sensitivity or action.
- Inhibition of insulin release via somatostatin abolished the hypoglycemic effect, and diabetic rats lacking endogenous insulin showed no response.
Conclusions:
- BTS 67 582 exerts a potent acute hypoglycemic effect in rats.
- The primary mechanism of action is stimulation of insulin release.
- The findings suggest BTS 67 582's potential as a therapeutic agent for glycemic control.